logo
logo

AmacaThera Announces Close of Oversubscribed Series A Financing to Advance a Novel Post-Operative, Nonopioid Pain Therapy in Clinical Trials

Feb 22, 2021•over 4 years ago

Round Type

series a

Toronto

Description

AmacaThera Inc. announced today that it has completed an oversubscribed US$10.3 million Series A financing to support development of AMT-143, the company’s lead clinical asset, and pipeline expansion. The Series A round was led by Lumira Ventures and includes a global investor syndicate of existing investors, Viva BioInnovator and Sprout BioVentures, as well as new investors, BDC Capital Women in Technology (WIT) Venture Fund, Inveready, MBX Capital, CR Capital Management, StandUp Ventures, and MaRS IAF.

Company Information

Company

Amaca Thera

Location

Toronto, Ontario, Canada

About

AmacaThera is a clinical-stage company based in Toronto. AmacaThera is redefining how therapeutics are delivered. AmacaThera has developed a platform hydrogel technology that addresses the critical problem of sustaining therapeutic delivery of pharmacological agents for multiple disease areas. AmacaThera’s lead product addresses post-operative pain and consequently may have an impact on the opioid crisis. AmacaThera is a spin-out company from Dr. Molly Shoichet’s laboratory at the University of Toronto. For more information, visit www.amacathera.com.